Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 19504 | 438 | 40.8 | 83% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 222 | 19941 | LYMPHANGIOGENESIS//ANGIOGENESIS//ENDOSTATIN |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | TSU 68 | Author keyword | 8 | 60% | 2% | 9 |
| 2 | APATINIB | Author keyword | 5 | 63% | 1% | 5 |
| 3 | MUCOCUTANEOUS TOXICITIES | Author keyword | 2 | 67% | 0% | 2 |
| 4 | MT BREAST GRP | Address | 2 | 50% | 1% | 3 |
| 5 | HER2 NEGATIVE | Author keyword | 2 | 31% | 1% | 5 |
| 6 | UNITA PATOL MAMMARIA | Address | 2 | 36% | 1% | 4 |
| 7 | SU006668 | Author keyword | 1 | 100% | 0% | 2 |
| 8 | UNITA OPERAT DETERMINANTI BIOMOL PROGNOSI TER | Address | 1 | 50% | 0% | 2 |
| 9 | WEATHERALL MOL ONCOL S | Address | 1 | 50% | 0% | 2 |
| 10 | CLIN TARGET VALIDAT | Address | 1 | 17% | 1% | 4 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | TSU 68 | 8 | 60% | 2% | 9 | Search TSU+68 | Search TSU+68 |
| 2 | APATINIB | 5 | 63% | 1% | 5 | Search APATINIB | Search APATINIB |
| 3 | MUCOCUTANEOUS TOXICITIES | 2 | 67% | 0% | 2 | Search MUCOCUTANEOUS+TOXICITIES | Search MUCOCUTANEOUS+TOXICITIES |
| 4 | HER2 NEGATIVE | 2 | 31% | 1% | 5 | Search HER2+NEGATIVE | Search HER2+NEGATIVE |
| 5 | SU006668 | 1 | 100% | 0% | 2 | Search SU006668 | Search SU006668 |
| 6 | ADJUVANT TAMOXIFEN TREATMENT | 1 | 50% | 0% | 1 | Search ADJUVANT+TAMOXIFEN+TREATMENT | Search ADJUVANT+TAMOXIFEN+TREATMENT |
| 7 | ADVANCED BREAST CANCER ABC | 1 | 50% | 0% | 1 | Search ADVANCED+BREAST+CANCER+ABC | Search ADVANCED+BREAST+CANCER+ABC |
| 8 | ANTHRACYCLINE RESISTANT BREAST CANCER | 1 | 50% | 0% | 1 | Search ANTHRACYCLINE+RESISTANT+BREAST+CANCER | Search ANTHRACYCLINE+RESISTANT+BREAST+CANCER |
| 9 | ANTITUMOR GROWTH AND METASTASIS | 1 | 50% | 0% | 1 | Search ANTITUMOR+GROWTH+AND+METASTASIS | Search ANTITUMOR+GROWTH+AND+METASTASIS |
| 10 | BEVACUZIMAB | 1 | 50% | 0% | 1 | Search BEVACUZIMAB | Search BEVACUZIMAB |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | PACLITAXEL PLUS BEVACIZUMAB | 10 | 25% | 8% | 36 |
| 2 | SU6668 | 9 | 59% | 2% | 10 |
| 3 | COMBINED BIOLOGICAL THERAPY | 5 | 45% | 2% | 9 |
| 4 | YN968D1 | 4 | 75% | 1% | 3 |
| 5 | LOCALLY RECURRENT | 4 | 22% | 4% | 16 |
| 6 | PLUS BEVACIZUMAB | 2 | 13% | 4% | 17 |
| 7 | BEVACIZUMAB PLUS DOCETAXEL | 2 | 67% | 0% | 2 |
| 8 | HER2 PROTOONCOGENE | 2 | 50% | 1% | 3 |
| 9 | HER2 NEGATIVE LOCALLY RECURRENT | 1 | 100% | 0% | 2 |
| 10 | TNBC | 1 | 100% | 0% | 2 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
|---|---|---|---|---|
| Antiangiogenesis Therapy for Breast Cancer: An Update and Perspectives from Clinical Trials | 2014 | 7 | 69 | 45% |
| Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials | 2012 | 32 | 70 | 33% |
| Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials | 2010 | 45 | 16 | 44% |
| Bevacizumab in the treatment of metastatic breast cancer: three case reports | 2011 | 1 | 5 | 100% |
| Efficacy of biological agents in metastatic triple-negative breast cancer | 2014 | 6 | 33 | 24% |
| Bevactumab Capecitabrin problem with breast cancer in the RIBBON-1 study | 2011 | 0 | 1 | 100% |
| Bevacizumab in the treatment of breast cancer | 2008 | 15 | 18 | 50% |
| Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model | 2015 | 1 | 69 | 22% |
| Treatment-Related Mortality With Bevacizumab in Cancer Patients A Meta-analysis | 2011 | 176 | 31 | 10% |
| Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer | 2012 | 5 | 33 | 42% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | MT BREAST GRP | 2 | 50% | 0.7% | 3 |
| 2 | UNITA PATOL MAMMARIA | 2 | 36% | 0.9% | 4 |
| 3 | UNITA OPERAT DETERMINANTI BIOMOL PROGNOSI TER | 1 | 50% | 0.5% | 2 |
| 4 | WEATHERALL MOL ONCOL S | 1 | 50% | 0.5% | 2 |
| 5 | CLIN TARGET VALIDAT | 1 | 17% | 0.9% | 4 |
| 6 | AVANCADO ONCOL | 1 | 50% | 0.2% | 1 |
| 7 | CLIN TARGETED THER Y | 1 | 50% | 0.2% | 1 |
| 8 | DIAG TREAT BREAST DIS | 1 | 50% | 0.2% | 1 |
| 9 | GESUNDHEIT OSTERREICH GMBH | 1 | 50% | 0.2% | 1 |
| 10 | HIST CYTOL | 1 | 50% | 0.2% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000246678 | METRONOMIC CHEMOTHERAPY//METRONOMIC//LOW DOSE METRONOMIC CHEMOTHERAPY |
| 2 | 0.0000219485 | PLASMA VEGF//MANCHESTER RENAL GRP//PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR |
| 3 | 0.0000210908 | OREGOVOMAB//AFLIBERCEPT//GI PERFORATION |
| 4 | 0.0000172136 | VEGF POLYMORPHISMS//VEGF POLYMORPHISM//RS2010963 |
| 5 | 0.0000168307 | FLT 1//VEGF RECEPTORS//VEGF165B |
| 6 | 0.0000161002 | MICROVESSEL DENSITY//MICROVESSEL COUNT//CHALKLEY |
| 7 | 0.0000141670 | SUNITINIB//METASTATIC RENAL CELL CARCINOMA//CARCINOMA RENAL CELL |
| 8 | 0.0000137480 | PEMETREXED//MULTITARGETED ANTIFOLATE//NONSQUAMOUS |
| 9 | 0.0000129690 | METASTATIC BREAST CANCER//VINORELBINE//DOCETAXEL |
| 10 | 0.0000126071 | TRASTUZUMAB//LAPATINIB//PERTUZUMAB |